Drug intelligence / Profile preview

haemagglutinin-strain a(h3n2)

Development stage
Unknown
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Intranasal, Intradermal, Subcutaneous
01

Overview

Haemagglutinin-strain A(H3N2) refers to the hemagglutinin (HA) surface glycoprotein derived from the influenza A virus subtype H3N2. HA is a class I viral fusion protein responsible for mediating viral entry into host cells by facilitating membrane fusion after endocytosis[3]. The H3N2 subtype is one of the major circulating strains causing seasonal influenza in humans and is included in annual flu vaccines[4][8]. The HA protein undergoes frequent antigenic drift through amino acid substitutions, especially at antigenic sites, allowing the virus to evade immune responses and necessitating regular updates to vaccine strains[1][5][2]. In vaccine formulations, purified or recombinant HA from specific H3N2 strains is used as an active component to induce protective immunity against circulating viruses.

Other names
haemagglutinin-strain a(h3n2)
02

Targets

α2,6-Sia (Alpha-2,6-linked sialic acid)HA (Hemagglutinin)Sialoglycan (Cell-surface sialoglycan)

Beyond the preview

Go deeper on haemagglutinin-strain a(h3n2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haemagglutinin-strain a(h3n2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call